IGF-1 receptor is down-regulated by sunitinib induces MDM2-dependent ubiquitination

FEBS Open Bio

Volumn 2, Issue , 2012, Pages 1-5

  Shen, Hongchang ^a   Fang, Yan ^b   Dong, Wei ^a   Mu, Xueru ^a   Liu, Qi ^a   Du, Jiajun ^a  

^a SHANDONG PROVINCIAL HOSPITAL AFFILIATED TO SHANDONG UNIVERSITY   (China)

^b SHANDONG UNIVERSITY   (China)

Author keywords

Insulin like growth factor; MDM2; Phosphorylation and ubiquitination; Tyrosine kinase inhibitor

Indexed keywords

MITOGEN ACTIVATED PROTEIN KINASE; PROTEASOME; PROTEIN KINASE B; PROTEIN MDM2; SMALL INTERFERING RNA; SOMATOMEDIN C RECEPTOR; SUNITINIB; SUTENT 11248; UNCLASSIFIED DRUG;

ARTICLE; CANCER GROWTH; CELL STRAIN HEK293; CONTROLLED STUDY; CULTURE MEDIUM; ENZYME PHOSPHORYLATION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; MALIGNANT TRANSFORMATION; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; RECEPTOR DOWN REGULATION; SIGNAL TRANSDUCTION; UBIQUITINATION;

EID: 84861213747     PISSN: 22115463     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.fob.2011.12.001     Document Type: Article

References (24)

1. Ouban A., Muraca P., Yeatman T., Coppola D. Expression and distribution of insulin-like growth factor-1 receptor in human carcinomas. Hum. Pathol. 2003, 34(8):803-808.
2. Parker A.S., Cheville J.C., Janney C.A., Cerhan J.R. High expression levels of insulin-like growth factor-I receptor predict poor survival among women with clear-cell renal cell carcinomas. Hum. Pathol. 2002, 33:801-805.
3. Spentzos D., Cannistra S.A., Grall F., Levine D.A., Pillay K., Libermann T.A., Mantzoros C.S. IGF axis gene expression patterns are prognostic of survival in epithelial ovarian cancer. Endocr. Relat. Cancer 2007, 14:781-790.
4. Hailey J., Maxwell E., Koukouras K., Bishop W.R., Pachter J.A., Wang Y. Neutralizing anti-insulin-like growth factor receptor 1 antibodies inhibit receptor function and induce receptor degradation in tumor cells. Mol. Cancer Ther. 2002, 1:1349-1353.
5. Sachdev D., Li S.L., Hartell J.S., Fujita-Yamaguchi Y., Miller J.S., Yee D. A chimeric humanized single-chain antibody against the type I insulin-like growth factor (IGF) receptor renders breast cancer cells refractory to the mitogenic effects of IGF-I. Cancer Res. 2003, 63:627-635.
6. Goetsch L., Gonzalez A., Leger O., Beck A., Pauwels P.J., Haeuw J.F., Corvaia N. A recombinant humanized anti-insulin-like growth factor receptor type I antibody (h7C10) enhances the antitumor activity of vinorelbine and anti-epidermal growth factor receptor therapy against human cancer xenografts. Int. J. Cancer 2005, 113:316-328.
7. Cohen P. Overview of the IGF-1 system. Horm. Res. 2006, 65(Suppl. 1):3-8.
8. Girnita A., Girnita L., del Prete F., Bartolazzi A., Larsson O., Axelson M. Cyclolignans as inhibitors of the insulin-like growth factor-1 receptor and malignant cell growth. Cancer Res. 2004, 64:236-242.
9. Girnita L., Girnita A., Larsson O. Mdm2-dependent ubiquitination and degradation of the insulin-like growth factor 1 receptor. Proc. Natl. Acad. Sci. 2003, 100:8247-8252.
10. Girnita L., Shenoy S.K., Sehat B., Vasilcanu R., Girnita A., Lefkowitz R.J., Larsson O. {beta}-Arrestin is crucial for ubiquitination and down-regulation of the insulin-like growth factor-1 receptor by acting as adaptor for the MDM2 E3 ligase. J. Biol. Chem. 2005, 280:24412-24419.
11. Vecchione A., Marchese A., Henry P., Rotin D., Morrione A. The Grb10/Nedd4 complex regulates ligand-induced ubiquitination and stability of the insulin-like growth factor I receptor. Mol. Cell. Biol. 2003, 23:3363-3372.
12. Mendel D.B., Laird A.D., Xin X., et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin. Cancer Res. 2003, 9:327-337.
13. Abrams T.J., Lee L.B., Murray L.J., Pryer N.K., Cherrington J.M. SU11248 inhibits KIT and platelet-derived growth factor receptor β in preclinical models of human small cell lung cancer. Mol. Cancer Ther. 2003, 2:471-478.
14. Kim D.W., Jo Y.S., Jung H.S., et al. An orally administered multitarget tyrosine kinase inhibitor, SU11248, is a novel potent inhibitor of thyroid oncogenic RET/papillary thyroid cancer kinases. J. Clin. Endocrinol. Metab. 2006, 91:4070-4076.
15. Homsi J., Daud A.I. Spectrum of activity and mechanism of action of VEGF/PDGF inhibitors. Cancer Control 2007, 14:285-294.
16. Pietras K., Sjoblom T., Rubin K., Heldin C.H., Ostman A. PDGF receptors as cancer drug targets. Cancer Cell 2003, 3:439-443.
17. Murray L.J., Abrams T.J., Long K.R., et al. SU11248 inhibits tumor growth and CSF-1R-dependent osteolysis in an experimental breast cancer bone metastasis model. Clin. Exp. Metastasis 2003, 20:757-766.
18. O'Farrell A.M., Abrams T.J., Yuen H.A., et al. SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. Blood 2003, 101:3597-3605.
19. Kim K.J., Li B., Winer J., et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 1993, 362:841-844.
20. Faivre S., Demetri G., Sargent W., Raymond E. Molecular basis for sunitinib efficacy and future clinical development. Nat. Rev. Drug Discov. 2007, 6:734-745.
21. Jones J.I., Clemmons D.R. Insulin-like growth factors and their binding proteins: biological actions. Endocr. Rev. 1995, 16:3-34.
22. LeRoith D., Werner H., Beitner-Johnson D. Molecular and cellular aspects of the insulin-like growth factor I receptor. Endocr. Rev. 1995, 16:143-163.
23. Baserga R., Hongo A., Rubini M. The IGF-I receptor in cell growth, transformation and apoptosis. Biochim. Biophys. Acta 1997, 1332:F105-26.
24. Sehat B., Andersson S., Girnita L., Larsson O. Identification of c-Cbl as a new ligase for insulin-like growth factor-I receptor with distinct roles from Mdm2 in receptor ubiquitination and endocytosis. Cancer Res. 2008, 68:5669-5677.